Sitagliptin - Merck & Co
Alternative Names: Glactiv; Januvia; MK-0431; MK-431; ONO-5435; Sitagliptin phosphate - Merck & Co; Tesavel; XeleviaLatest Information Update: 07 Oct 2022
At a glance
- Originator Merck & Co; Merck Sharp & Dohme
- Developer Banyu; Merck & Co; Merck Sharp & Dohme; Ono Pharmaceutical; University of Colorado at Denver; Washington University School of Medicine
- Class Antihyperglycaemics; Fluorobenzenes; Ketones; Pyrazines; Small molecules; Triazoles
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 30 Sep 2022 US Court of Appeals for the Federal Circuit rules in favor of Merck in a patent infringement suit against Viatris for sitagliptin phosphate
- 23 Sep 2022 Merck enters into patent litigation settlement agreements with multiple generic companies
- 23 Sep 2022 US District Court rules in favor of Merck in a patent infringement suit against Viatris for sitagliptin phosphate